Drugs / CYB003
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05385783 | Aug 2022 → Oct 2023 | major depressive disorder | Cybin IRL Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06820723 | Nov 2025 → Mar 2027 expected | anxiety, major depressive disorder | Ohio State University | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06793397 | Dec 2025 → Mar 2027 expected | major depressive disorder | Cybin IRL Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06605105 | Jul 2025 → Mar 2028 expected | major depressive disorder | Cybin IRL Limited | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06564818 | Dec 2024 → Aug 2026 overdue | major depressive disorder | Cybin IRL Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYB003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06793397 ↗ |
| Route | Oral | “ascending oral doses of CYB003” NCT05385783 ↗ |